HARLAND DEBORAH 4
4 · BICYCLE THERAPEUTICS plc · Filed May 30, 2019
Insider Transaction Report
Form 4
HARLAND DEBORAH
Director
Transactions
- Conversion
Series B1 Preferred Shares
2019-05-28−636,366→ 0 total(indirect: See Footnote)→ Ordinary Shares (636,366 underlying) - Conversion
Ordinary Shares
2019-05-28+893,195→ 893,195 total(indirect: See Footnote) - Conversion
Ordinary Shares
2019-05-28+636,366→ 1,529,561 total(indirect: See Footnote) - Purchase
Ordinary Shares
2019-05-28$14.00/sh+385,714$5,399,996→ 1,915,275 total(indirect: See Footnote) - Conversion
Series A Preferred Shares
2019-05-28−893,195→ 0 total(indirect: See Footnote)→ Ordinary Shares (893,195 underlying)
Footnotes (2)
- [F1]Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein. Deborah Harland holds the title of Vice President at S.R. One, Limited and is an employee of GlaxoSmithKline Services Unlimited, a wholly-owned subsidiary of GlaxoSmithKline plc. Ms. Harland disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of her pecuniary interest therein.